Supraflex a cardiac drug eluting stent designed and manufactured in India has been confirmed to be at par with Abbott’s Xience through an investigators-driven study called 'TALENT'. Dr Patrick Serruys a globally renowned cardiology researcher was the chair for the TALENT trial. The findings of the TALENT trial were presented at the ‘late breaking trial session’ at Transcatheter Cardiovascular Therapeutics 2018 (TCT) the largest global conference of cardiologist currently underway in San Diego USA. This study was conducted in 7 countries - United Kingdom Netherlands Poland Spain Italy Hungary and Bulgaria - across 23 renowned centres with a sample size